Androgen-Binding Proteins from Human Hyperplastic Prostate as Evaluated by Electrophoresis

References

• Attramadal A, Tveter K J, Weddington S C, Djose-land O, Naess O, Hansson V, Torgersen O. Androgen binding and metabolism in the human prostate. Vitam Horm 1975; 33: 247–264
   PubMedGoogle Scholar
• Barahona Ba E., ñuelos J, Solís J, Bermúdez JA. Preliminary characterization of a new androgen binding protein in human seminal plasma. Arch Androl 1980; 4: 235–248
   PubMedGoogle Scholar
• Bartke A, Hafiez A A, Bex F J, Delterio S. Hormonal interactions in regulation of androgen secretion. Biol Reprod 1978; 18: 44–54
   PubMed Web of Science ®Google Scholar
• Bonne C, Raynaud JP. Methyltrienolone: A specific ligand for cellular androgen receptors. Steroids 1975; 26: 227–232
   PubMed Web of Science ®Google Scholar
• Bonne C, Raynaud JP. Assay of androgen binding sites by exchange with methyltrienolone (R 1881). Steroids 1976; 27: 497–507
   PubMed Web of Science ®Google Scholar
• Corvol P L, Chrambach A, Rodbard D, Bardin CW. Physical properties and binding capacity of testosterone-binding globulin in human plasma determined by polyacrylamide gel electrophoresis. J Biol Chem 1971; 246: 3435–3443
   PubMed Web of Science ®Google Scholar
• Cowan R A, Cowan S K, Giles C A, Grant JK. Prostatic distribution of SHBG and CBG in benign hyperplasia. J Endocrinol 1976; 71: 121–131
   PubMed Web of Science ®Google Scholar
• Fang S, Anderson K, Liao MS. Receptor proteins for androgens. On the role of specific proteins in selective retention of 17β-hydroxy-5α-androstan-3-one by rat ventral prostate in vivo and in vitro. J Biol Chem 1969; 244: 6584–6595
   PubMed Web of Science ®Google Scholar
• Geller J, Cantor T, Albert J. Evidence for a specific dihydrotestosterone-binding cytosol receptor in the human prostate. J Clin Endocrinol Metab 1975; 41: 854–862
   PubMed Web of Science ®Google Scholar
• Gustafsson J A, Ekman P, Snochowski M, Zetterberg Pousette A., Hogberg B. Correlation between clinical response to hormone therapy and steroid receptor content in prostatic cancer. Cancer RES 1978; 38: 4345–4348
   PubMed Web of Science ®Google Scholar
• Hansson V. Uptake and retention of testosterone and 5α-dihydrotestosterone by rat ventral prostate in vitro. Acta Endocrinol (Copenh) 1971; 68: 89–97
   PubMedGoogle Scholar
• Hicks L L, Walsh PC. A microassay for the measurement of androgen receptors in human prostatic tissue. Steroids 1979; 33: 389–405
   PubMed Web of Science ®Google Scholar
• Iqbal M J, Johnson MW. Purification and characterization of human sex hormone binding globulin. J Steroid Biochem 1979; 10: 535–540
   PubMedGoogle Scholar
• Ishimaru T, Pages L, Horton R. Altered metabolism of androgens in elderly men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1977; 45: 695–701
   PubMed Web of Science ®Google Scholar
• Jensen EV (1965) In Proceedings of the Second International Congress of Endocrinology, London, 1964. Excerpta Medica, Amsterdam, 420
   Google Scholar
• Jensen E V, Suzuki T, Kawashima T, Stumpf W E, Jungblut DeSombre ER. A two-step mechanism for the interaction of estradiol with rat uterus. Proc Natl Acad Sci USA 1968; 59: 632–638
   PubMed Web of Science ®Google Scholar
• Jegou B, Le Gac-Jegou F. Androgen binding protein in the seminal plasma of some mammalian species. J Endocrinol 1978; 77: 267–268
   PubMed Web of Science ®Google Scholar
• Krieg M, Bartsch W, Janssen W, Voigt KD. A comparative study of binding metabolism and endogenous levels of androgens in normal hyperplastic and carcinomatous human prostate. J Steroid Biochem 1979; 11: 615–624
   PubMedGoogle Scholar
• Lasnitz KI. Metabolism and action of steroid hormones on human benign prostatic hyperplasia and prostatic carcinoma grown in organ culture. J Steroid Biochem 1979; 11: 625–630
   PubMedGoogle Scholar
• Lowry O H, Rosebrough N J, Lewis-Farr A, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Mann T, Lutwak-Mann C. Biochemistry of seminal plasma and male accessory fluids; application to andrological problems. Male Reproduc-live Function and Semen. Springer-Verlag, New York 1981; 269–336
   Google Scholar
• Meikle A W, Collier E S, Middleton R G, Fang SM. Supranormal nuclear content of 5α-dihydrotestosterone in benign hyperplastic prostate of humans. J Clin Endocrinol Metab 1980; 51: 945–947
   PubMed Web of Science ®Google Scholar
• McLean W S, Smith A A, Hansson V, Naess O, Nay-feh S N, French FS. Further characterization of the androgen receptor in rat testis. Mol Cell Endocrinol 1976; 4: 239–355
   PubMed Web of Science ®Google Scholar
• Nesbit R M, Baum WC. Endocrine control of prostatic carcinoma. JAMA 1950; 143: 1317–1320
   PubMed Web of Science ®Google Scholar
• Nisula B C, Dunn JF. Measurement of the testosterone binding parameters for both testosterone-estradiol binding globulin and albumin in individual serum samples. Steroids 1979; 34: 771–791
   PubMed Web of Science ®Google Scholar
• Plymate S R, Fariss B L, Smith M L, Jacob W T, Matej LA. Seminal fluid androgen binding protein. Andrologia 1981; 13: 308–313
   PubMed Web of Science ®Google Scholar
• Polakoski K L, Zaneveld L JD. Biochemical examination of the human ejaculate. Techniques of Human Andrology, ESE Hafez. Elsevier North Holland, Amsterdam 1977; 265–286
   Google Scholar
• Purvis K, Calandra R, Hansson V. Intratesticular transport of androgens. Androgens and Antiandrogens, L Martini, M Mota. Raven, New York 1977; 37–51
   Google Scholar
• Rosen V, Jung I, Baulieu E-E, Robel P. Androgen binding proteins in human benign prostatic hypertrophy. J Clin Endocrinol Metab 1975; 41: 761–770
   PubMed Web of Science ®Google Scholar
• Schmidt H, Noack I, Voigt KD. Metabolism and mode of action of androgens in target tissues of male rats. II. Mode of action of testosterone and 5α-dihydrotestosterone at a cellular level on seminal vesicles and prostates of rats. Acta Endocrinol (Copenh) 1972; 69: 165–173
   PubMedGoogle Scholar
• Shain SA, Boesel RW. Androgen receptor content of the normal and hyperplastic canine prostate. J Clin Invest 1978; 61: 654–660
   PubMed Web of Science ®Google Scholar
• Shain S A, Boesel R W, Lamm D L, Radwin HM. Characterization of unoccupied (R) and occupied (RA) androgen binding components of the hyperplastic human prostate. Steroids 1978; 31: 541–556
   PubMed Web of Science ®Google Scholar
• Siiteri P K, Wilson JD. Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J Clin Invest 1970; 49: 1737–1745
   PubMed Web of Science ®Google Scholar
• Snochowski M, Poustte A, Ekman P, Bression D, Andersson L, Hogberg B, Gustafsson J-A. Characterization and measurement of the androgen receptor in human benign prostatic hyperplasia and prostatic carcinoma. J Clin Endocrinol Metab 1977; 45: 920–930
   PubMed Web of Science ®Google Scholar
• Unhjem O. Studies on the uptake and binding of 5α-dihydrotestosterone by rat ventral prostate cell nuclei in vitro. Acta Endocrinol (Copenh) 1970; 65: 533–540
   PubMedGoogle Scholar
• Vermeulen A. Transport and distribution of androgens at different ages. Androgens and Antiandrogens, L Martini, M Mota. Raven, New York 1977; 53–65
   Google Scholar